Reprint

Advances in the Treatment of Kidney and Upper Urinary Tract Cancers

Edited by
March 2024
174 pages
  • ISBN978-3-7258-0553-2 (Hardback)
  • ISBN978-3-7258-0554-9 (PDF)

This book is a reprint of the Special Issue Advances in the Treatment of Kidney and Upper Urinary Tract Cancers that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Kidney and Upper Tract Urinary Cancers (UTUCs) are diseases of increasing population coverage, the treatment of which is undergoing a continuous process of evolution. A characteristic feature of renal cell cancer (RCC) treatment is the significant heterogeneity of patients (including different stages of local advancement and different locations of metastases). Importantly, it is estimated that up to 30% of newly diagnosed RCC cases are patients with disseminated disease at the time of diagnosis. Therefore, predicting the response to modern treatment remains the unmet need of modern urologic oncology. Recent advancements in systematic treatment, i.e., immunotherapy, shed additional light on adjuvant treatment to be implemented in new clinical scenarios, including localized disease.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
renal cell carcinoma; risk models; survival analysis; charlson comorbidity index; systemic inflammatory markers; upper tract urothelial carcinoma; UTUC; sPD-L1; soluble programmed death ligand-1; biomarker; prognosis; immune checkpoint inhibitor therapy; chemotherapy; radical nephroureterectomy; focal therapy; kidney cancer; thermal ablation; renal carcinoma; RCC; PD-1; PD-L1; nivolumab; kidney tumor; systemic inflammatory response syndrome; nephrectomy; globotriaosylceramide; rhamnose-binding lectin; sunitinib; renal cell carcinoma; brain metastases; kidney cancer; renal cell carcinoma; neurosurgery; targeted therapy; basement membrane; diagnostic; renal cancer; lncRNA; prognostic model; biomarker; immunotherapy; prostate cancer; transplant; immunosuppression; progression; metastatic prostate cancer; upper tract urothelial cancer; Balkan endemic nephropathy; morphology; CKs; CD44; tyrosine kinase inhibitors (TKI); cabozantinib; metastatic renal cell carcinoma (mRCC); adverse events; predictive factor; n/a